BCL2 and myelofibrosis: In this review, we focus on a novel orally bioavailable, antiapoptotic Bcl-2 inhibitor, navitoclax, the clinical rationale for its use in the treatment of myelofibrosis, and its outcomes in clinical trials with other therapeutic agents for relapsed or refractory cases of myelofibrosis.